NASDAQ · SERVICES-MEDICAL LABORATORIES
BioNexus Gene Lab Corp. BGLC
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$7.4M
▼ 21.9% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-35.2%
Net margin · FY25
-40.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 7.4M
Revenue, FY2025 · full 8-year series below
Revenue
Net income
The company lost 40 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-35.2%
Return on equity, FY2025
ROE
Operating margin-39.9%
Net margin-40.2%
Return on assets-30.3%
Each USD of equity lost 35 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−8.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−12.1%
−8.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 9.3M
total assets, end of FY2025
Total assetsUSD 9.3M
EquityUSD 8.6M
CashUSD 2.5M
Current ratio10.46×
Equity funds 93% of total assets.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
Income tax $B
0.0
−0.0
−0.0
−0.0
−0.0
·
0.0
−0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
EPS, diluted $
·
−0.09
−0.17
·
·
0.01
0.00
0.00
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
−35.2
−17.8
−32.2
−5.1
10.9
28.1
−18.6
1.7
Shares out B
0.00
0.00
0.02
0.01
0.17
0.17
0.10
0.07
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
26 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 1 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed